NorthRock Partners LLC Sells 78 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NorthRock Partners LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 263 shares of the biopharmaceutical company’s stock after selling 78 shares during the period. NorthRock Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $253,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. West Paces Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares in the last quarter. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. MCF Advisors LLC increased its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, BOK Financial Private Wealth Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $37,000. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on REGN shares. Barclays boosted their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Cantor Fitzgerald restated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday. UBS Group upped their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Finally, StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,038.77.

Regeneron Pharmaceuticals Trading Down 1.6 %

Regeneron Pharmaceuticals stock traded down $17.94 during trading hours on Monday, reaching $1,082.11. 431,230 shares of the company’s stock were exchanged, compared to its average volume of 472,697. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm’s 50 day simple moving average is $1,016.19 and its 200 day simple moving average is $967.07. Regeneron Pharmaceuticals, Inc. has a twelve month low of $715.54 and a twelve month high of $1,106.16. The firm has a market capitalization of $119.24 billion, a PE ratio of 31.97, a PEG ratio of 2.27 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.